BIRD - A Microsatellite for Hot Spot Detection

The BIRD mission of the German Aerospace Centre shall demonstrate the scientific and technological value and the technical and programmatic feasibility of a remote sensing small satellite mission under low budget constraints. The payload -a new generation of cooled infrared detectors- is adapted to the mission objective - the investigation of hot spots caused by forest fires or volcanic activities completed by the diagnosis of vegetation conditions and changes. BIRD -the Bispectral Infra-Red Detector- is a three-axis stabilised spacecraft within a volume of 0.21 m3 and a mass of 88 kg. In flight configuration with one fixed and two deployed solar panels, providing 40 W average and 200 W peak power, the spacecraft dimensions are 620x 1600x 620 mm3 • Although compatible to several launchers due to the highly compact design, the launch is scheduled for mid 2000 as a piggy-back payload. To fit in this time scale a modular design was chosen for parallel development, manufacturing and integration of all functional segments. The article gives an overview of the mission objectives and some of the main design aspects as well as shows the status of work of the space segment

PASSIVE THERMAL CONTROL SYSTEMS FOR SPACE INSTRUMENTS MAKING – SCIENTIFIC BACKGROUND, QUALIFICATION, EXPLOITATION IN SPACE

Passive thermal control systems (TCS) are one of obligatory system of any space mission, used as on large spacecraft and microsatellites Supporting of required temperature range for space instruments is supported by rational design of TCS with optimal choice of main thermal control components such as multilayer insulation, optical coatings, heat conductive elements, heat insulation supports, thermal conductive gaskets, radiating surfaces and other elements. New ideology in TCS design has come after appearance of new element – heat pipe(s) which is a super heat conductive thermal conductor with constant or variable thermal properties

Solar-Sail Navigation: Estimation of Force, Moments, and Optical Parameters

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/77367/1/AIAA-24340-772.pd

A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

© 2021 The Authors.[Background]: Venetoclax is a selective BCL-2 inhibitor with clinical activity in relapsed/refractory multiple myeloma (RRMM). Combinations of venetoclax with agents that have complementary mechanisms of action may improve venetoclax efficacy in RRMM. This study evaluated venetoclax with pomalidomide and dexamethasone (VenPd) in RRMM. [Patients and Methods]: This phase II open label study (NCT03567616) evaluated VenPd in patients with RRMM who had received ≥ 1 prior therapy and were refractory to lenalidomide. Venetoclax was administered orally daily for days 1 to 28, pomalidomide was administered orally daily for days 1 to 21, and dexamethasone was administered weekly for each 28-day cycle. The primary objective was to characterize the safety and tolerability of VenPd. The secondary objectives were to evaluate the efficacy and pharmacokinetics. The study was terminated early due to partial clinical hold and decision to pursue biomarker driven strategy. [Results]: Eight patients were enrolled. Patients had a median age of 67.5 years. All patients received 400 mg venetoclax; 4 patients experienced dose-limiting toxicities and the dose was not escalated. All patients had a grade ≥ 3 adverse event, and the most common was neutropenia (n = 6); cytopenias were the most prevalent adverse events. Five patients (63%) had a confirmed response, and the median duration of response was 12.9 months. The median progression-free survival was 10.5 months. [Conclusions]: Given the limited enrollment, no clear safety or efficacy conclusions about VenPd can be drawn. Preliminary safety data, particularly the occurrence of cytopenias, can be used to guide dosing strategies for future combinations of venetoclax with immunomodulatory agents.AbbVie Inc is a private corporation, and funding is not associated with a grant number. Funding information is correct as stated